Amakuru y'inganda

Ubushakashatsi buherutse gukorwa bwerekana umusaruro mwiza wo kuvura CD7-targeted chimeric antigen receptor (CAR) T cells mu kuvura abarwayi ba T-cell acute lymphoblastic leukemia (T-ALL) na T-cell lymphoblastic lymphoma (T-LBL) bafite.

Inama ngarukamwaka ya 66 y’Umuryango w’Abanyamerika w’Ubuvuzi bw’Amaraso (ASH) izaba kuva ku ya 7 kugeza ku ya 10 Ukuboza 2024, ibera mu Kigo cy’Amakoraniro cya San Diego, igaragaza ubushakashatsi bugezweho n’iterambere mu bijyanye n’amaraso.

Nubwo hari imbogamizi zikomeje mu iterambere ry’inganda n’ubucuruzi, imbogamizi za CAR-T therapy ziri gukemurwa n’uburyo bushya butanga icyizere: Uburyo bwo kuvura kanseri y’ibibyimba (TIL). Ubu buryo bugaragaza igihe gishya mu kurwanya ibibyimba bikomeye.

Uburyo bushya bwo kuvura kanseri bushobora kandi kuvura no gusubiza ubudahangarwa bw'umubiri kugira ngo butange ihumure ry'igihe kirekire cyangwa ndetse bunakize indwara zimwe na zimwe ziterwa n'ubwiyongere bw'umubiri.

Inama ngarukamwaka ya 65 y’Umuryango w’Abanyamerika w’Ubuvuzi bw’Amazi (ASH) yabaye kuva ku ya 9 kugeza ku ya 12 Ukuboza 2023, i San Diego, muri Amerika. Nk’igikorwa kinini kandi cyuzuye cyane ku isi mu bijyanye n’indwara z’amaraso, gikurura impuguke n’abahanga baturutse impande zose...